OmicronSARS-CoV-2

Saya Moriyama1, Yuki Anraku2, Shunta Taminishi3

  • 1Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan. sayamrym@niid.go.jp.

Nature communications
|July 14, 2023
PubMed
概括

科学家们在SARS-CoV-2 Omicron亚变体上确定了关键抗体目标,从而设计了弹性抗体. 这项研究为开发有效的抗病毒治疗方法提供了洞察力.